Dexcom Q1 Revenue Up 15%, Gross Margin Climbs to 63.5%
Dexcom reported 15% Q1 revenue growth and boosted gross margin to 63.5% from 57.5%, ending the quarter with $2.4 billion in cash. The new G7 15 Day system and type 2 non-insulin share gains contrast with slower US market expansion and uncertain CMS coverage timing.
1. Q1 Financial Performance
Dexcom posted 15% year-over-year revenue growth for Q1 2026, with gross profit margin rising to 63.5% from 57.5% in Q1 2025. Improved manufacturing efficiencies and operational execution drove the margin expansion.
2. Product Launch and Market Share Gains
The Dexcom G7 15 Day system was successfully introduced, offering enhanced sensor algorithms and extended wear time, fueling share gains in the type 2 non-insulin segment. Strong global demand for CGM products supported these gains.
3. US Market Dynamics and Coverage Uncertainty
US CGM market growth moderated due to no major coverage expansions and a four-quarter streak without record new patient starts. CMS coverage timing for type 2 non-insulin patients remains uncertain, posing a risk to near-term adoption.
4. Strong Cash Position
Dexcom ended the quarter with approximately $2.4 billion in cash and cash equivalents, underscoring its solid financial position. Robust free cash flow generation funds ongoing R&D and market expansion initiatives.